Spontaneous HCV clearance: an association with gender, age, viral genotypes, infection transmission routes, and markers of HBV and HIV


Aim. To determine the rate of spontaneous recovery depending on gender, age, prior icteric hepatitis, infection transmission routes, HCV genotype, markers of HBV and HIV.
Subjects and methods. A humoral immunity response to core antigen and nonstructural viral proteins was assessed in patients with HCV clearance and in a group of patients with chronic hepatitis C (CHC). Two hundred and thirty-eight anti-HCV positive patients were examined. Spontaneous viral clearance (SVC) was diagnosed in 27 (12.1%) patients; a false-positive anti-HCV reaction was seen in 15. The spontaneous recovery group comprised young patients with a female predominance: 66 versus 41.9% in the CHC group. Results. 25.2% of the examinees with SVC had a history of the icteric form of acute viral hepatitis. There were no significant differences between HCV genotype and disease outcome. The markers of retrospectively sustained HBV infection were more detectable in the spontaneous recovery group: anti-HBc 48.1% and anti-HBs 14.8%; these were 32.6 and 8.7%, respectively. HIV co-infection reduced the likelihood of recovery. The determination of antibodies to nonstructural viral proteins could state their rare identification in patients with spontaneous HCV clearance (anti-NS3 HCV, 100%; SVC, 42.3%; NS4 HBC, 95.5%; SVC, 30.8%; p < 0.0001). AntiNS5 was only in 15.4% of the recovered patients and in 89.8% of the patients with chronic infections (p < 0.0001).
Conclusion. Rare detection of anti-NS5 may serve as an additional serological marker indicating to spontaneous HCV clearance in anti-HCV positive patients.


  1. Wang C. C., Krantz E., Klarquist J. et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J. Infect. Dis. 2007; 196: 1474-1482.
  2. Micallef J. M., Kaldor J. M., Dore G. J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral Hepatit. 2006; 13(1): 34-41.
  3. Scott J. D., McMahon B. J., Bruden D. et al. High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska Natives. Clin. infect. Dis. 2006; 42: 945-952.
  4. Thomas D. L., Astemborski J., Rai R. M. et al. The natural history of hepatitis C virus infection. J. A. M. A. 2000; 284(4): 450-456.
  5. Condotti D., Temple J., Sarkodie F., Allain J. P. Frequent recovery and broad genotype 2 diversity characterize hepatitis C virus infection in Ghana. West Africa. J. Virol. 2003; 77(14): 7914-7923.
  6. Федорченко С. В., Заневская Л. И., Бурма Н. М. и др. Латентная HBV-инфекция у разовых доноров крови. Вопр. вирусол. 2008; 53(1): 23-25.
  7. Bark J., Rekacewicz C. E., Hosseiny et al. Higher clearance of hepatitis C virus infection in females compared with males. Gut 2006; 55(8): 1183-1187.
  8. Grebely G., Conway B., Raffe J. D. et al. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can. J. Gastroenterol. 2007; 21(7): 447-451.
  9. Keating S., Coughlan S., Connell J. et al. Hepatitis C viral clearance in an intravenous drug-using cohort in the Dublin area. Jr. J. Med. Sci. 2005; 174(1): 37-41.
  10. Mazzeo C., Azzaroli F., Giovanelli S. et al. Ten year incidence of HCV infection in northern Italy and frequence of spontaneous viral clearance. Gut 2003; 52(70): 1030-1034.
  11. Watanabe H., Saito T., Shinzawa H. et al. Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: a population - based cohort study. J. Med. Virol. 2003; 71: 56-61.
  12. Barrett S., Ryan E., Crowe j. Association of the HLA DRB 101 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. Hepatology 1999; 30(6): 979-983.
  13. Busch M. P., Glynn S. A., Stramer S. L. et al. Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors. Transfusion 2006; 46(3): 469-475.
  14. Inque G., Horiike N., Michitaka K. et al. Hepatitis C virus clearance is prominent in women in an endemic area. J. Gastroenterol. Hepatol. 2000; 15(9); 1054-1058.
  15. Wietzke-Braun P., Manhardt L. B., Rosenberger A. et al. Spontaneous elimination of hepatitis C virus infection: a retrospective study on demograghic, clinical and serological correlates. Wld J. Gastroenterol. 2007; 13(31): 4224-4229.
  16. Piasecki B. A., Lewis J. D., Reddy K. R. et al. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology 2004; 40(4): 892-899.
  17. Harris H. E., Elbrige K. P., Harbour S. et al. Does the clinical outcome of hepatitis C infection vary with infecting hepatitis C virus type? J. Viral. Hepat. 2007; 14(3): 213-220.
  18. Sagnelli E., Coppola N., Messina V. et al. HBV superinfection in hepatitis C virus chronic carriers, viral, interaction, and clinical course. Hepatology 2002; 36: 1285-1291.
  19. Behrens S. E., Tomei L., Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. Embo J. 1996; 15: 12-22.
  20. Zhang H. Q., Wang G. H., Chen K. et al. Studies on the correlation between titer of antibodies against different functions of hepatitis C virus and HCV RNA of chronic patients. Zhonghua Gan Zang Bing Za Zhi 2003; 11(12): 754-755.
  21. Beld M., Penning M., van Putten M. et al. Quantitative antibody responses to stucfural (Core) and nonstructural (NS3, NS4, NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood. Hepatology 1999; 29(4): 1288-1298.
  22. Ishii K. J., Ishibashi M., Ohtake T. et al. Characterization of antibodies against core, NS3, NS4, NS5 region of hepatitis C virus in patients with hepatitis C. Rinsho Byori 1997; 45(12): 1156-1162.
  23. Toyoda H., Kumada T., Kiriyama S. et al. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection therapy. Clin. Infect. Dis. 2005; 40: 49-54.



Abstract: 173

Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2010 Fedorchenko S.V., Martynovich T.L., Lyashok O.V., Karyuk Z.A., Yanchenko V.I., Fedorchenko S.V., Martynovich T.L., Lyashok O.V., Karyuk Z.A., Yanchenko V.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies